Literature DB >> 15672427

Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases.

S Truant1, D Huglo, M Hebbar, O Ernst, M Steinling, F-R Pruvot.   

Abstract

BACKGROUND: The aim of this study was to assess the additional value of information provided by positron emission tomography (PET) with [(18)F]fluoro-2-deoxy-D-glucose (FDG) over that provided by computed tomography (CT) in patients with resectable liver metastases from colorectal cancer.
METHODS: Between October 2001 and November 2002, a prospective double-blind comparison of preoperative FDG-PET and thoracoabdominal CT was performed in 53 patients with potentially resectable liver metastases from colorectal cancer. All resected metastases were subjected to histological examination.
RESULTS: Histological examination confirmed the presence of malignant or benign lesions detected by PET and/or CT in 95 per cent of instances. Overall sensitivity (78 per cent) and accuracy (88 per cent) of PET were equivalent to those of CT (76 and 86 per cent respectively). The sensitivity of PET was equivalent to that of CT for hepatic sites (both 79 per cent), but was superior for extrahepatic abdominal sites (63 and 25 per cent respectively). PET provided additional information in five patients, mainly by revealing abdominal extrahepatic metastases, but falsely upstaged three patients.
CONCLUSION: Whole-body FDG-PET may identify unrecognized extrahepatic metastases in patients with potentially resectable liver metastases imaged by CT. However, additional information provided by PET is not as reliable as suggested by earlier retrospective studies. Copyright (c) 2005 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15672427     DOI: 10.1002/bjs.4843

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  27 in total

1.  Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer.

Authors:  Andreas Andreou; Luca Viganò; Giuseppe Zimmitti; Daniel Seehofer; Martin Dreyer; Andreas Pascher; Marcus Bahra; Wenzel Schoening; Volker Schmitz; Peter C Thuss-Patience; Timm Denecke; Gero Puhl; Jean-Nicolas Vauthey; Peter Neuhaus; Lorenzo Capussotti; Johann Pratschke; Sven-Christian Schmidt
Journal:  J Gastrointest Surg       Date:  2014-08-27       Impact factor: 3.452

2.  PET: too much of a good thing? Does the plethora of choices impact on patient management?

Authors:  Chaitanya Divgi; Neeta Pandit-Taskar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

3.  Guidelines for resection of colorectal cancer liver metastases.

Authors:  O J Garden; M Rees; G J Poston; D Mirza; M Saunders; J Ledermann; J N Primrose; R W Parks
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 4.  Colorectal hepatic metastasis: Evolving therapies.

Authors:  Francisco Igor B Macedo; Tafadzwa Makarawo
Journal:  World J Hepatol       Date:  2014-07-27

5.  Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease.

Authors:  Motaz Qadan; Michael I D'Angelica
Journal:  Curr Colorectal Cancer Rep       Date:  2015-08-18

6.  Selection for hepatic resection of colorectal liver metastases: expert consensus statement.

Authors:  Reid B Adams; Thomas A Aloia; Evelyne Loyer; Timothy M Pawlik; Bachir Taouli; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2013-02       Impact factor: 3.647

7.  Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy.

Authors:  Andreas Andreou; Thomas A Aloia; Antoine Brouquet; Paxton V Dickson; Giuseppe Zimmitti; Dipen M Maru; Scott Kopetz; Evelyne M Loyer; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2013-06       Impact factor: 12.969

8.  The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.

Authors:  G Kong; C Jackson; D M Koh; V Lewington; B Sharma; G Brown; D Cunningham; G J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-18       Impact factor: 9.236

9.  Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Authors:  Andreas Andreou; Scott Kopetz; Dipen M Maru; Su S Chen; Giuseppe Zimmitti; Antoine Brouquet; Junichi Shindoh; Steven A Curley; Christopher Garrett; Michael J Overman; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

Review 10.  Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases.

Authors:  Yolanda Y L Yang; James W Fleshman; Steven M Strasberg
Journal:  J Gastrointest Surg       Date:  2007-07       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.